Outcome after first relapse in children with acute lymphoblastic leukemia: A population-based study of 315 patients from the nordic society of pediatric hematology and oncology (NOPHO)-Reference-Cited by-同舟云学术

Outcome after first relapse in children with acute lymphoblastic leukemia: A population-based study of 315 patients from the nordic society of pediatric hematology and oncology (NOPHO)

Published:1995-11 Issue:5 Volume:25 Page:372-378
ISSN:0098-1532
Container-title:Medical and Pediatric Oncology
language:en
Short-container-title:Med. Pediatr. Oncol.

Author:

Schroeder H.,Garwicz S.,Kristinsson J.,Siimes M. A.,Wesenberg F.,Gustafsson G.

Publisher

Wiley

Subject

Cancer Research,Oncology,Pediatrics, Perinatology and Child Health

Reference19 articles.

1. Bone marrow relapse occurring as first relapse in children with acute lymphoblastic leukemia

2. The significance of an isolated central nervous system relapse, occurring as first relapse in children with acute lymphoblastic leukemia

3. Chemotherapy for bone marrow relapse of childhood acute lymphoblastic leukemia

4. Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85). A relapse study of the BFM group

5. A Population-Based Study of Childhood Acute Lymphoblastic Leukemia Diagnosed from July 1981 through June 1985 in the Five Nordic Countries.

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Temporal changes in incidence of relapse and outcome after relapse of childhood acute lymphoblastic leukemia over three decades; a Nordic population-based cohort study;Leukemia;2022-03-21

2. Neoplasms of the Testis;Urologic Surgical Pathology;2020

3. Treatment-related mortality in relapsed childhood acute lymphoblastic leukemia;Pediatric Blood & Cancer;2017-12-12

4. Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia in Children;Thomas’ Hematopoietic Cell Transplantation;2016-01-01

5. Non-Hodgkin’s Lymphomas in Children: 25-Year Clinical Experience;Clinical oncohematology;2016